Effects of NAD restoration on neurovascular coupling in community dwelling older adults - age-related cognitive decline has emerged as one of the major public health challenges of our time

Active Project Grant Awarded Last action

Award ID
R01AG075834
Recipient
Awarding agency
Obligated
$3,176,988

Award facts

Assistance listing
93.866 Aging Research
Completion date 90% complete
Place of performance
Oklahoma City, OK 73117, USA

Award details come from USAspending.gov.

Description

IT is well known that normal cognitive function requires an adequate blood supply to support neuronal activity. In the healthy young brain, cerebral blood flow is rapidly adjusted to meet the increased oxygen and nutrient demands of active brain regions via a homeostatic mechanism known as neurovascular coupling (NVC, or functional hyperemia). Preclinical and clinical studies demonstrate that NVC is impaired in normal aging, and experimentally induced impairment of NVC responses in young animals results in cognitive impairment. Restoration of NVC in these animals by targeted pharmacological treatments improves cognitive function. Testing specific interventions in humans that have demonstrated efficacy in animal models is a reasonable and prudent approach that may improve impaired NVC and may be the key to developing effective therapies to reverse or prevent age-related cognitive decline and alzheimer's disease/ alzheimer's disease related dementias (ad/ADRD) in older adults. Endothelial dysfunction and impairment of NVC responses have been associated with increases in the production of reactive oxygen species (ROS) that are one of the well-defined 'hallmarks of aging'. Nicotinamide adenine dinucleotide (NAD) is one of the major regulators of ROS and has been shown to attenuate ROS production. Our preliminary studies indicate that NAD levels are profoundly reduced in brain vascular endothelial cells of aged mice and that restoration of NAD levels in normal aged mice (equivalent of =60 years of age in humans) using an NAD precursor rescues age-related endothelial dysfunction, restores NVC responses and attenuates cognitive decline. Age-related NAD depletion, endothelial dysfunction, and impaired NVC responses are observed in older adults even in the absence of predisposing vascular pathology. Although supplementation with the NAD precursor, nicotinamide riboside (NR), has been reported to increase blood cell NAD levels in humans, effects on endothelial function and NVC responses have not been investigated. Addressing this scientific GAP is essential to further develop our understanding of the etiology of NVC impairment and establish its role in the genesis of cognitive decline in aging and ad/ADRD. Our central hypothesis is that restoration of NAD levels with NR in older adults will improve NVC responses and micro- and macrovascular endothelial function. This hypothesis will be tested by assessing the effects of treatment with oral NR (1G/day per OS for 8 weeks) or placebo (8 weeks) in community dwelling older adults (60-85 years of age) in a randomized, double-blinded, placebo-controlled, parallel study design. These studies will determine whether NR supplementation alleviates endothelial and neurovascular dysfunction and, potentially, cognitive decline. We anticipate that identifying NAD dysregulation during aging as a driver of vascular dysfunction will not only result in development of new and urgently needed tools to treat vascular dysfunction in aging, but also advance research related to the etiology of ad/ADRD.

Transactions

Action Obligated Date
Amendment $645,067
Amendment $642,605
Amendment $626,440
Amendment $609,215
Amendment $0
Original award $653,661

Subawards

Subrecipient Amount Awarded
Oklahoma Medical Research Foundation Dr. Wren’s lab at the Oklahoma Medical Research Foundation will be the site for statistical and bioinformatics analysis site for the data gathered in this… $25,339
The Trustees Of The University Of Pennsylvania The Baur lab will receive whole blood and serum samples from all main cohort study participants at all time points. The Baur lab will directly measure NAD+… $230,159
The Trustees Of The University Of Pennsylvania This subcontract will support effort, core and equipment usage fees, and supplies for the Penn personnel. Dr. Baur will lead the Penn team. The Baur lab will… $230,159
Oklahoma Medical Research Foundation Dr. Wren’s lab at the Oklahoma Medical Research Foundation will be the site for statistical and bioinformatics analysis site for the data gathered in this… $25,339
Oklahoma Medical Research Foundation Dr. Wren’s lab at the Oklahoma Medical Research Foundation will be the site for statistical and bioinformatics analysis site for the data gathered in… $27,356
The Trustees Of The University Of Pennsylvania The Baur lab will receive whole blood and serum samples from all main cohort study participants at all time points. The Baur lab will directly measure NAD+… $208,552

Quick answers

Who received award R01AG075834?

R01AG075834 was awarded to University Of Oklahoma by National Institute on Aging (National Institutes of Health) on August 10, 2022.

How much is award R01AG075834 worth?

$3,176,988 has been obligated on R01AG075834.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award